Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo

Background and Objects: Bruton's tyrosine kinase inhibitors are commonly used and effective for lymphoma and chronic lymphocytic leukemia (CLL). Ibrutinib might improve the effect of anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CD19 CAR) T-cell therapy in lymphoma, but t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Xiupeng, Liu, Meijing, Lv, Cuicui, Li, Yeqiong, Chen, Lan, Zhang, Jin, Mu, Juan, Deng, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580088/
https://www.ncbi.nlm.nih.gov/pubmed/36254554
http://dx.doi.org/10.1177/15330338221133224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580088/
https://www.ncbi.nlm.nih.gov/pubmed/36254554
http://dx.doi.org/10.1177/15330338221133224

Ejemplares similares